KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Cash from Operations (2016 - 2025)

Historic Cash from Operations for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q3 2025 value amounting to -$84.6 million.

  • CRISPR Therapeutics AG's Cash from Operations rose 2083.84% to -$84.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$302.5 million, marking a year-over-year decrease of 6020.46%. This contributed to the annual value of -$142.8 million for FY2024, which is 4516.6% up from last year.
  • Per CRISPR Therapeutics AG's latest filing, its Cash from Operations stood at -$84.6 million for Q3 2025, which was up 2083.84% from -$113.9 million recorded in Q2 2025.
  • CRISPR Therapeutics AG's Cash from Operations' 5-year high stood at $807.0 million during Q2 2021, with a 5-year trough of -$142.0 million in Q2 2022.
  • Its 5-year average for Cash from Operations is -$32.2 million, with a median of -$95.6 million in 2024.
  • In the last 5 years, CRISPR Therapeutics AG's Cash from Operations surged by 285624.85% in 2021 and then crashed by 16824.82% in 2024.
  • Quarter analysis of 5 years shows CRISPR Therapeutics AG's Cash from Operations stood at -$86.0 million in 2021, then crashed by 31.72% to -$113.3 million in 2022, then increased by 15.23% to -$96.1 million in 2023, then skyrocketed by 47.92% to -$50.0 million in 2024, then plummeted by 69.16% to -$84.6 million in 2025.
  • Its Cash from Operations was -$84.6 million in Q3 2025, compared to -$113.9 million in Q2 2025 and -$53.9 million in Q1 2025.